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ABSTRACT OF THE DISSERTATION 
 
A Novel Exo-Proteomic Approach to the Study of Traumatic Brain Injury 
by 
Ron B. Moyron 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, September 2018 
Dr. Nathan R. Wall, Chairperson 
 
 
Concussions and Traumatic Brain Injuries (TBI) are significant health concerns 
and affect a wide cross section of society. Current diagnostic criteria and modalities, such 
as brain imaging and subjective measures of consciousness such as the Glasgow Coma 
Scale (GCS) score, are insufficient to properly diagnose the full spectrum of head 
injuries. Assessment of injury severity and outcome are further complicated by the vast 
array of symptoms, many of which mimic those displayed by other disorders. It is 
important to possess a better diagnostic tool for head injury triage and outcome 
prediction. One current line of inquiry seeks to discover a “traumatic brain injury 
biomarker”, or a number of them, in order to differentiate the healthy patient from the 
concussed individual. However, there are challenges in proteomic analysis of neuronal 
proteins. Current methods, such as sampling cerebral spinal fluid via lumbar puncture, 
are both invasive and carry risk of injury. Discovery of trauma-specific biomarkers 
present in peripheral blood may present a viable alternative. However, the likely 
degradation of neuronal proteins in the peripheral circulation is an obstacle. Exosomes, 
small membrane vesicles known to carry proteins and injury-specific biomarkers, may 
help provide an ideal modality for the study of the TBI. The current work sought to 
 xiii 
assess the utility of an exo-proteomic approach for the study of traumatic brain injury. 
Blood samples taken from trauma patients admitted to a Level 1 Trauma Center were 
stratified according to GCS score and their exo-proteomic content was analyzed via mass 
spectrometry. Results indicated differential exosomal protein expression in patients 
corresponding to injury severity, as categorized by GCS score. Based on these findings, 
we believe that exo-proteomic analysis of patients with differing level of injury severity 
lends itself well to the discovery of potential trauma-specific biomarkers that can aid in 
the establishment of a true differential diagnostic for the full spectrum of concussion and 
traumatic brain injuries. 
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In the early portion of the 21
st
 Century, after decades of neglect and an almost 
complete lack of concern, concussions and head trauma (and their aftermath) have come 
to dominate the public consciousness. With the conflicts in Afghanistan and Iraq, and the 
alarming injury rates and subsequent deaths linked to contact sports, particularly 
American football, the onus has been placed on researchers to discover new and novel 
ways to address this significant and growing problem. There are estimates that every 21 
seconds in the United States someone sustains a traumatic brain injury (TBI) with 50,000 
attributable deaths each year. These numbers account for one-third of all injury-related 
deaths in the U.S. and more than 1 million people seeking medical care for TBI annually. 
More than 5 million Americans are living with TBI-related disabilities and the United 
States spends an estimated $56 billion per year treating the after-effects of this condition
1
. 
TBI can result from a multitude of causes, the most common being motor vehicle 
accidents, falls and/or assaults, exposure to explosions (i.e. soldiers serving in combat) 
and penetrating head trauma (gunshot wounds etc.). The terms mild TBI (mTBI) and 
concussion have often been used interchangeably and the traditional, societal perception 
of these injuries has been that they are insipid, or even inconsequential in nature. 
However, our growing body of knowledge is beginning to paint a very different, and 
decidedly starker, picture. TBI, even of the mTBI variety, can cause significant damage 
to both white matter and axons 
2
 and repeated episodes of mTBI and/or subconcussive 
trauma can induce significant worsening of clinical symptoms that strongly resemble 
both Parkinson’s and Alzheimer’s disease among others. 
Severe TBI tend to be more straightforward than less severe forms such as mTBI. 
These less severe injuries have confounded accurate, concise definition and are incredibly 
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difficult to diagnose. Clinicians and researchers have struggled to agree on a single, 
standard definition of mTBI. This is most likely due to the vast amount of diversity and 
lack of specificity in symptomology. All-too-often, those who have suffered an acute 
mTBI present with symptoms that mimic a variety of other conditions, some even 
psychological in nature. This heterogeneity in symptomology and the fact that many 
patients with mTBI have symptoms that closely mimic other disorders make many 
mTBIs almost impossible to accurately detect. Most mTBI patients recover well and do 
not suffer from lingering symptoms. However, many who have suffered an mTBI 
experience worsening symptoms that continue to progress and become more severe 
manifestations of emotional, psychological and physical trauma. Estimates are that 15% 
of patients with mTBI develop persistent cognitive dysfunction 
2
. Currently, the 
American Congress of Rehabilitation Medicine defines an mTBI as, a traumatically 
induced physiological disruption of brain function, as manifested by at least one of the 
following: loss of consciousness, any loss of memory for events immediately before or 
after the event, focal neurologic deficit that may or may not be transient, but where the 
severity of the injury does not exceed a loss of consciousness of approximately 30 min or 
less, an initial Glasgow Coma Scale (GCS) score of 13–15 and post-traumatic amnesia 
not greater than 24 h 
3
. 
Concussions and mTBI have been called a “silent epidemic” 4  as both 
concussions and subconcussive events are often undiagnosed or unreported altogether. 
Mild traumatic brain injuries are also alarmingly common. It has been estimated that 
more than 1.5 million Americans sustain mTBI without a subsequent loss of 
consciousness and without the need for hospitalization. An equal or greater number 
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sustain an injury that impairs consciousness but is not severe enough to require long-term 
hospitalization. Mild Traumatic brain injury affects up to 10 million people globally and 
accounts for 70-90% of all TBI cases 
3
. 
Blasts, vehicle crashes, and other mechanisms place soldiers, athletes and us all at 
risk for TBI.  A mild TBI or mTBI is characterized by mechanical injury to the head with 
brief loss of consciousness or altered mental status 
5
.  Surveys of soldiers who have 
recently returned from active duty indicate that up to 16% reported that a loss of 
consciousness was associated with their injuries 
6
. Soldiers with TBI, particularly those 
who had lost consciousness with their injury are more likely to meet criteria for 
posttraumatic stress disorder (PTSD) and major depression and poor general health.  
They also report more lost workdays, medical visits and a higher number of 
postconcussive symptoms than do soldiers that experienced other types of injuries 
5, 6
.  
Athletes suffer repetitive concussive and subconcussive brain trauma as well, and as a 
result they suffer executive dysfunction, memory impairment, depression and suicidality, 
apathy, poor impulse control, and eventually dementia 
7
.  It is important to note that most 
individuals with mTBI recover within 3-6 months of the injury.  However, a subset will 
develop persistent neuropsychiatric symptoms 
8, 9
.  Unfortunately, most individuals with 
mTBI do not seek out and thus do not receive rehabilitation and thus many become 
permanently disabled 
5
.  Although it is difficult to detect an mTBI simply using a clinical 
examination, there are studies now which suggest that early identification and treatment 
of the symptoms can improve outcomes 
10, 11
.  It is therefore imperative to devote effort to 
the identification of novel biomarkers that will enhance early TBI detection, management 
and therapeutic response that could be tailored to the soldiers, athletes or the community.  
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Important to mTBI diagnosis and management is to determine an optimal combination of 
clinical indicators or biomarkers that could detect injury early with both high specificity 
and sensitivity and with limited invasiveness.  In spite of the availability of a number of 
gene products considered as promising biomarkers (S100B and neuron specific enolase 
(NSE)), it is recognized that their combined use with the available clinical information is 
still insufficient for early diagnosis and for guiding individualized therapeutic 
interventions and predicting outcomes 
12
.  However, there is growing interest in using 
proteomic approaches to identify serum autoantibodies recognizing trauma-associated 
antigens (TrAA), as well as serum microvesicles called exosomes and their content, as 
serological biomarkers 
13-19
. This interest stems from the notion that these blood 
components are considered “sensors” of molecular events associated with pathology 16, 20, 
21
. 
In addition to clinical variables available at the time of injury, the potential utility 
of quantifying serum biomarkers of structural damage or as mediators of cellular, 
biochemical, or molecular secondary injury cascades for predicting outcome after TBI 
has been investigated 
4, 22
.  S100B is a calcium-binding protein found in glial cells, 
predominantly astrocytes, and at physiologic concentrations has been shown to provide 
both neurotrophic and neuroprotective effects. Elevated presence of S100B in peripheral 
blood and/or cerebral spinal fluid (CSF) may indicate neuronal damage and possible 
blood brain barrier disruption 
23
.  In acute TBI and post-acute scenarios, S100B has been 
documented to be elevated and as a result may lack specificity, better serving as a marker 
for polytrauma.  NSE is a glycolytic enzyme that catalyzes the conversion of 2-
phosphoglycerate to phosphoenolpyruvate (PEP). The neuron specific isomer of enolase 
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is found primarily in neuron cytoplasm. In TBI patients, NSE may indicate neuronal 
damage as NSE has been reported elevated in patients with mTBI. However, NSE lacks 
sensitivity and specificity with its levels shown to be elevated in non-trauma patients due 
to a variety of causes 
24
. Additionally, an increased NSE level can result from hemolysis, 
a common occurrence in trauma cases. There is also a poor correlation between NSE 
serum levels and Glasgow Outcome Scale (a longer term evaluative measure when 
compared with GCS) 
25
. 
Together, S100B and NSE have been shown to be sensitive to cranial pathology 
after mTBI with strong negative predictive values 
5
. In addition, elevated levels of these 
biomarkers have been linked to poor predictive outcomes up to 12 months post injury.  
Testing these biomarkers has not been adopted clinically because of their low levels, 
specificity and reports that non-cranial injuries also contribute to elevations in these two 
markers 
26
.  It is therefore imperative that proteome-profiling & immunoseroproteomics 
approaches, currently considered the most promising strategy for the identification of 
serum biomarkers 
13, 14, 16, 17
 be adapted and applied to TBI and mTBI.  The application of 
such approaches in the context of soldiers, athletes or the general population has never 
been done before. 
The list of potential biomarkers for TBI, though small, continues to grow with the 
top investigated targets, besides S100B and NSE, being Glial Fibrillary Acidic Protein 
(GFAP), Myelin Basic Protein (MBP), and Ubiquitin C-terminal Hydrolase-L1 (UCH-
L1) 
27
. GFAP is an intermediate filament protein, encoded by the GFAP gene, that is 
expressed in many cell types in the CNS, most particularly glial cells but also astrocytes 
and ependymal cells 
28
. GFAP is a major component of the astrocyte cytoskeleton which 
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is acutely elevated following mTBI 
29, 30
. Presence of GFAP in CSF and peripheral blood 
in trauma patients may suggest astrocyte damage and possible blood brain barrier (BBB) 
disruption 
31
.  GFAP seems to have both high sensitivity and specificity but has not yet 
been shown to correlate with longer-term disruption.  MBP, found in myelin and known 
to play a key role in myelination, is one of the most abundant CNS proteins 
32
. MBP 
levels are elevated in trauma patients post TBI 
33
. Higher MBP levels may suggest axonal 
injury and damage and may be related to poor outcome in trauma patients 
34
. Detection of 
aberrant levels of serum MBP may take 48-72 hours and may be somewhat impractical 
for diagnostic purposes at this point.  Cleaved tau (C-tau), a microtubule associated 
protein that is expressed in CNS axons, has been recorded post TBI 
35
.  A presence of C-
tau in plasma may suggest hyperphosphorylation and formation of neurofibrillary tangles 
that have been seen in post mortem samples of patients with chronic traumatic 
encephalopathy (CTE) 
36
. Although C-tau has been correlated with TBI, to date its 
presence was not indicative of intracranial lesions on CT scans of patients with head 
trauma. Furthermore, C-tau has not been proven to be an accurate predictor of post 
concussive syndrome (PCS) and longer-term recovery 
36, 37
. UCH-L1 is a 
deubiquitinating enzyme found in the cytoplasm of interneurons and is the newest 
proposed biomarker in TBI. Its presence may suggest neuronal damage and BBB 
disruption as its presence is abundant in neurons 
38
. UCH-L1 is also known in the neuron 
literature as neuronal-specific protein gene product (PGP 9.3) and in studies performed in 
CSF, an inverse relationship exists as its presence increased as GCS decreased. This 
relationship indicates a direct association between UCH-L1 and trauma levels 
38
. 
However, to date, little is known about UCH-L1 levels in trauma patients 
27, 37, 39
 making 
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UCH-L1 a very promising target in TBI studies.  Produced by calpain and caspase 3 
alpha 2, spectrin breakdown products (SBDP) are found in presynaptic terminals and 
axons 
37
. SBDP presence in trauma patients, especially those with subarachnoid 
hemorrhage (SAH) may suggest cellular necrosis following brain injury 
40
. Along with 
UCH-L1, SBDPs are promising proteins for head trauma analysis. 
Despite the recent increase in interest and funding in the study of head trauma, the 
field is in its infancy. There are currently no widely accepted clinical biomarkers known 
to be indicative of head trauma.  In spite of the availability of a number of gene products 
considered as promising biomarkers (described above), it is recognized that their 
combined use with the available clinical information is still insufficient for early 
diagnosis and for guiding individualized therapeutic interventions and predicting 
outcomes 
12
.  Much has been made of the urgent need to discover a novel diagnostic tool 
in order to alleviate the high costs of radiologic testing and expedite the treatment 
process.  Compounding the difficulty in the diagnosis of concussion and the more mild 
forms of TBI, where there may exist no findings on a CT scan, is the fact that the etiology 
of the continuum from concussion to PCS to CTE is a mystery. What allows one trauma 
patient with a concussion or head injury to recover quickly and be largely asymptomatic 
while another, with similar acute presentation, may suffer long term or permanent 
disability is unknown. We are only just beginning to understand the most severe end of 
the head trauma spectrum, the CTE exhibited by retired boxers and American football 
players. But we do not yet understand all of the factors that lead from one, or multiple, 
concussive events to the tragic disabilities exhibited by some of our greatest icons like 
 9 
Muhammad Ali and the brave men and women who served our country in the Armed 
services.  
Rather than finding one single novel traumatic biomarker, the proverbial “magic 
bullet”, it is quite possible that the beginnings of an answer may lie in the adoption, or 
formalization, of a panel of trauma-specific proteins. It may be possible to combine one 
or more of the aforementioned proteins, along with yet undiscovered biomarkers, and 
integrate them with post injury assessment and therapy to stem the tide of this 
increasingly frightening epidemic. 
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Abstract 
Traumatic Brain Injuries (TBI) are among the most misdiagnosed and 
underreported types of head trauma. The potential long-term impact of undiagnosed or 
incorrectly identified concussions and other head injuries are potentially devastating, as 
evidenced by the increasing societal burden exhibited by soldiers returning from combat 
and athletes in contact sports. Concussions and TBI are notoriously difficult to correctly 
diagnose and prognosis for these injuries is poorly understood. In order to increase the 
likelihood of successful diagnosis, treatment, and prediction of outcomes, a definitive 
differential diagnosis will need to be established. The establishment of a “trauma–specific 
profile” or a panel of known trauma markers will significantly aid in this goal. Small 
membrane vesicles called exosomes have been shown to contain proteins and injury-
specific biomarkers.  In the future it is possible that they could become an important tool, 
utilized for their diagnostic and therapeutic potential. 
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Significance of the Study 
Research is increasingly focusing on the triage and assessment of all manner of 
Traumatic Brain Injuries (TBI). The inherent difficulty in the differential diagnosis of 
head traumas is well understood as the heterogeneity of symptomatic presentation, the 
significant number of unreported injuries, and the disparate etiologies inherent in the 
injuries greatly increase the risk for misdiagnosis.  Most current proteomic approaches 
focus on assessing the small number of currently known markers of neuronal injury either 
individually or, at most, in pairs. In addition, many studies focus on detection of the 
presence of these few markers in cerebral spinal fluid (CSF). These approaches, while 
valid, present significant clinical challenges as the difficulty of CSF sample collection, 
and its inherent dangers, are well known. Discovery of trauma-specific biomarkers that 
might be present in a peripheral blood sample could serve as a de-facto “liquid biopsy” 
for concussion or TBI could greatly aid clinicians in proper differential diagnosis and 
assessment of head injury.  However, the likelihood of the degradation of most neuronal 
proteins in the peripheral blood presents significant challenges. An exo-proteomic 
approach lends itself well to an examination of injury-specific proteins that otherwise 
might not be present in peripheral blood at the realistic time frame of injury assessment 
and triage.  
 
Introduction 
Concussions and mild Traumatic Brain Injuries (mTBI) are garnering greater 
recognition and focus due to their widespread impact. According to estimates from the 
Centers for Disease Control and Prevention (CDC), approximately 1.7 million Americans 
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sustain TBI every year. TBI also contributes to about a third of all injury-related deaths, 
resulting in over 52,000 deaths a year 
1
. Perhaps more alarming are estimates that those 
people with TBI who do not seek treatment account for a quarter of all those who sustain 
a TBI in the United States 
1
. Classification of TBI (mild, moderate, or severe) is based 
upon a patient’s responsiveness as described by their score on the Glasgow Comma Scale 
(GCS): some authors stratify according to the following criteria, persons with GCS scores 
of 3–8 are classified with a severe TBI, those with scores of 9–12 are classified with a 
moderate TBI, and those with scores of 13–15 are classified with a mild TBI 2. However, 
the modern applicability of these gradations is debatable as the schema was developed 
over 40 years ago 
3
. TBI can result from a wide variety of causes including (but not 
limited to): motor vehicle collisions, blast-induced injury, falls, gunshot wounds, assaults, 
and other penetrating trauma.  TBI has traditionally been viewed as a single, transitory 
event with limited, episodic effect. However, due to its vast heterogeneity of symptom 
presentation and lengthy duration of dysfunction, TBI is now being viewed as a disease 
with significant potential for devastating long-term impact 
4-8
. Mild traumatic brain 
injuries are also alarmingly common. It has been estimated that more than 1.5 million 
Americans sustain mTBI without a subsequent loss of consciousness and without the 
need for hospitalization. An equal or greater number sustain an injury that impairs 
consciousness but is not severe enough to require long- term hospitalization. Mild 
Traumatic brain injury affects up to 10 million people globally and accounts for 70-90% 
of all TBI cases 
3
. Concussions and mTBI have been called a “silent epidemic” 4 as both 
concussions and sub concussive events are often undiagnosed or unreported altogether. 
Evidence is increasing that a crucial means of cell-cell and cell-extracellular 
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communication within the microenvironment that makes up the site of trauma is through 
the release and uptake of small extracellular vesicles (EVs) called exosomes.  Exosomes 
contain a subset of the originating cells proteins and RNAs 
9
, but compared to their cells 
of origin, these exosome are more stable and can cross the blood brain barrier 
10
. 
Exosomes contain on the surface of their membranes, proteins that act to present antigen 
to immune cells and produce various cell signals to recipient cells, either surrounding or 
distal, resulting in the interaction and deposition of the biomaterials they contain
11
.  In 
this study we identified exosomal protein contents from the plasma of GCS-stratified 
patients in order to identify an injury severity specific marker. Future studies of these 
markers may aid in the treatment decisions and severity monitoring for individuals 
having suffered a possible head trauma. 
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Experimental Methods 
Patient Samples 
A total of 78 patients were included for this study.  Any patient admitted to the 
Emergency Department of our Level 1 Trauma Center as a result of generalized trauma 
was considered eligible for admission to this study. Common mechanisms of injury 
included (but were not limited to): auto and motorcycle accidents, auto vs. pedestrian 
incidents, falls, assaults, knife injuries, and gunshot wounds.  Participants were selected 
by the Acute Care Surgery service, and peripheral blood samples were taken at 
admission, and at 24 and 48-hour intervals. Patients were stratified according to GCS and 
placed in the following categories: No significant injury (GCS:15; n= 36), Mild to 
Moderate Injury (GCS: 9-14; n= 17), and Severe Injury (GCS: 3-8; n= 25). Our original 
categorization schema stratified patients in four GCS categories (GCS:15, No Significant 
Injury; GCS:13-14, Mild Injury; GCS:9-12, Moderate Injury; and GCS:3-8, Severe 
Injury) rather than the three listed (A, B/C, and D). However, due to an extremely limited 
number of available patient samples in the Moderate Injury (GCS:9-12) classification, it 
was decided that the best way to approach sample analysis was to aggregate Groups B 
(GCS:13,14) and C (GCS: 9-12) and therefore the group entitled B/C was formed. For the 
purposes of our analysis we designated the GCS assessed at 0 hour as the score used for 
categorization. Since this decision occurred after sample collection, data for these groups 
is listed as Group B/C. Changes in GCS subsequent to triage and trauma assessment did 
not affect the categorical placement of the patient samples. Blood was collected in 
vacuum tubes containing sodium heparin and processed according to our previously 
established protocol
12
 and under the full approval of Loma Linda Universities 
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Institutional Review Board with participating subjects’ permissions obtained  
 
Patient Sample Aggregation 
After patient samples were collected, an equal amount of plasma from each 
sample was combined with samples from other members of the same trauma severity 
category in a single 1.75ml Eppendorf tube belonging to each specific group. Group A’s 
aggregated sample contained plasma aliquots from 36 patients (27.4 microliters from 
each patient), Group B/C’s aggregated sample contained 17 patients (58.8 microliters 
from each patient), and Group D’s aggregated sample contained 25 patient samples (40.0 
microliters from each patient).  All patient samples analyzed were those from the 24-hour 
time point. Each respective Eppendorf was labeled and the raw, untreated plasma 
aggregates were sent to SBI (Systems BioSciences, Inc. Mountain View CA) for 
exosome separation and analysis. 
 
Exosome Isolation and Characterization 
Exosomes were isolated using ExoQuick®, a commercial exosome precipitation 
reagent (Systems BioSciences, Inc. Mountain View CA), following the manufacturer’s 
protocol. Briefly, plasma samples from individual patients in each GCS group were 
pooled and incubated with ExoQuick® overnight at 4°C. Solutions were then centrifuged 
at 17,000 x g for 5min and the supernatant discarded. Pellets were resuspended in 100ul 
of 1xPBS and analyzed. Analysis of particle size and concentration was determined using 
a NS300 Nanosight imager (Malvern Instruments, Inc. Westborough MA) and run at a 
dilution of 1:1000. 
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Protein Profiling Sample Preparation 
Exosomes pellets were lysed in 300μL modified RIPA buffer (2.0% SDS, 150mM 
NaCl, 50mM Tris, pH 8.5, 1X Complete Protease inhibitor (Roche, South San Francisco, 
CA) at 100°C for 15 minutes. The lysate was clarified by centrifugation and the protein 
concentration determined by Qubit fluorometry (Invitrogen, Carlsbad, CA). 10μg of 
extracted protein was processed by SDS-PAGE using 10% Bis Tris NuPage mini-gel 
(Invitrogen, Carlsbad, CA) in the MES buffer system. The migration window (2cm lane) 
was excised and in-gel digestion performed using a ProGest robot (DigiLab, 
Marlsbouough, MA) with the following protocol: samples were washed with 25mM 
ammonium bicarbonate followed by acetonitrile. Reduced with 10mM dithiothreitol at 
60°C followed by alkylation with 50mM iodoacetamide at RT. Digested with sequencing 
grade trypsin (Promega, Madison, WI) at 37°C for 4h. Quenched with formic acid and 
the supernatant was analyzed directly without further processing.  
 
Mass Spectrometry  
Digested samples were analyzed by nano LC-MS/MS with a Waters NanoAcquity 
HPLC system (Waters Corporation, Milford, MA) interfaced to a ThermoFisher Q 
Exactive (Thermo Fisher Scientific Inc., Canoga Park, CA. Peptides were loaded on a 
trapping column and eluted over a 75μm analytical column at 350nL/min using a 2hr 
reverse phase gradient; both columns were packed with Luna resin (Phenomenex, 
Torrance, CA). The mass spectrometer was operated in data-dependent mode, with the 
Orbitrap operating at 60,000 FWHM and 17,500 FWHM for MS and MS/MS 
respectively. The fifteen most abundant ions were selected for MS/MS.  
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Data Analysis 
Scaffold software (Version 4.7, Proteome Software, Inc., Portland, OR) was used 
to quantitatively and qualitatively analyze proteomic results. For the purposes of our 
analysis the following criteria were utilized: 1.0 False Discovery Rate (FDR), 3.0 as the 
minimum number of peptides, and 1.0 FDR as the peptide threshold. Although lower 
thresholds yielded a greater number of proteins, it was decided that a higher level of 
stringency was preferable in order to assess the feasibility of the exo-proteomic model for 
the purposes of our trauma study. 
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Results 
 
Exosomes are Abundantly Present In Plasma and Concentration is Constant between 
GCS Groups. 
In order to obtain pooled exosomes, an equal amount of plasma from each 
individual patient in the GCS group (as described above) was collected and incubated 
with ExoQuick® and centrifuged. Vesicles pelleted by this method were then analyzed 
by nanoparticle tracking analysis (NTA). This showed, in all three groups, a relatively 
narrow size distribution with both the mode and median lying within the exosome 
defined size range (Table I, Figure 1). Group A had a mode of 114.3nm and mean of 
126.9nm. Group B/C had a mode diameter of 105.7nm and a mean of 128.6nm. Group D 
had a mode of 110.1nm and mean of 130.6nm. Concentrations of exosomes between the 
groups was also constant with 2.37x10
11
 particles per mL in group A, 2.38x10
11
 particles 
per mL in group B/C, and 2.04x10
11
 particles per mL in group D.  
 
Plasma-derived Exosomes from Trauma Patients (TrEx) Contain Potential 
Biomarkers. 
HPLC analysis of plasma-derived exosomes from 78 trauma patients yielded 186 
total categorized proteins (thresholds: 1.0 FDR, 3 peptide minimum, 1.0 FDR peptide 
threshold) (Figure 2, Table II). Analysis of these results using Scaffold 4, determined 
the number of proteins attributable to biological functions (Figure 3A).   
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Table I. Exosome Analysis of The Patient Groups, Size and Concentration. 
 
Group Size (nm) 
Mode/Mean 
Concentration 
(particles/ml) 
A 114.3±5.9/126.9±2.8 2.37x10
11
±2.28x10
9
 
B/C 105.7±0.8/128.6±1.7 2.38x10
11
±1.08x10
10
 
D 110.1±1.6/130.6±1.0 2.04x10
11
±7.13x10
9
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Figure 1. Nanoparticle Size and Concentration as Analyzed on the NTA300 
Nanosight.  A. Nanoparticle size of plasma vesicles shown as the mean, mode, and 
the smallest (D10), middle (D50), and largest particle populations (D90) for 
individual groups and composite.  B. Comparison of peaks corresponding to the most 
abundant vesicular subpopulations. 
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Figure 2. Exosomal Protein Enrichment was Monitored in Each Sample by Mass 
Spectrometry. Trauma changes were assessed by comparing within the GCS, trauma-
specific, exosomal proteomes. A Venn diagram shows the comparison in terms of 
exosome proteomes. 
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Table II. Exosomal Proteins Found in All Patients. 
PROTEINS ACCESSION NUMBER MW 
Bio View:Identified Proteins (186/231)<BR>Including 0 
Decoys Accession Number 
Molecular 
Weight 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 sp|P01024|CO3_HUMAN 187 kDa 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M 
PE=1 SV=3 sp|P01023|A2MG_HUMAN 163 kDa 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 sp|P02768|ALBU_HUMAN (+2) 69 kDa 
Apolipoprotein B-100 OS=Homo sapiens GN=APOB 
PE=1 SV=2 sp|P04114|APOB_HUMAN 516 kDa 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 sp|P01857|IGHG1_HUMAN 36 kDa 
Ig kappa chain C region OS=Homo sapiens GN=IGKC 
PE=1 SV=1 sp|P01834|IGKC_HUMAN 12 kDa 
Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 
SV=2 sp|P02675|FIBB_HUMAN 56 kDa 
Complement C4-B OS=Homo sapiens GN=C4B PE=1 
SV=2 sp|P0C0L5|CO4B_HUMAN 193 kDa 
Ig gamma-2 chain C region OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 sp|P01859|IGHG2_HUMAN 36 kDa 
Fibrinogen gamma chain OS=Homo sapiens GN=FGG 
PE=1 SV=3 sp|P02679|FIBG_HUMAN 52 kDa 
Fibrinogen alpha chain OS=Homo sapiens GN=FGA 
PE=1 SV=2 sp|P02671|FIBA_HUMAN 95 kDa 
Complement factor H OS=Homo sapiens GN=CFH PE=1 
SV=4 sp|P08603|CFAH_HUMAN 139 kDa 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 sp|P02787|TRFE_HUMAN 77 kDa 
Ig mu chain C region OS=Homo sapiens GN=IGHM 
PE=1 SV=3 sp|P01871|IGHM_HUMAN 49 kDa 
Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 sp|P01031|CO5_HUMAN 188 kDa 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 sp|P00450|CERU_HUMAN 122 kDa 
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 sp|P00747|PLMN_HUMAN 91 kDa 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 
PE=1 SV=3 sp|P01009|A1AT_HUMAN 47 kDa 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 sp|P01876|IGHA1_HUMAN 38 kDa 
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 sp|P02751|FINC_HUMAN 263 kDa 
C4b-binding protein alpha chain OS=Homo sapiens 
GN=C4BPA PE=1 SV=2 sp|P04003|C4BPA_HUMAN 67 kDa 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 
SV=1 sp|P02647|APOA1_HUMAN 31 kDa 
Immunoglobulin lambda-like polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 SV=2 sp|B9A064|IGLL5_HUMAN 23 kDa 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 sp|P00738|HPT_HUMAN 45 kDa 
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG 
PE=1 SV=1 sp|P04196|HRG_HUMAN 60 kDa 
Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 sp|P00734|THRB_HUMAN 70 kDa 
Ig gamma-3 chain C region OS=Homo sapiens sp|P01860|IGHG3_HUMAN 41 kDa 
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GN=IGHG3 PE=1 SV=2 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB 
PE=1 SV=2 sp|P68871|HBB_HUMAN 16 kDa 
Ig kappa chain V-III region HAH OS=Homo sapiens PE=2 
SV=1 sp|P18135|KV312_HUMAN 14 kDa 
Complement component C6 OS=Homo sapiens GN=C6 
PE=1 SV=3 sp|P13671|CO6_HUMAN 105 kDa 
Ig gamma-4 chain C region OS=Homo sapiens 
GN=IGHG4 PE=1 SV=1 sp|P01861|IGHG4_HUMAN 36 kDa 
Complement C1r subcomponent OS=Homo sapiens 
GN=C1R PE=1 SV=2 sp|P00736|C1R_HUMAN 80 kDa 
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 
SV=1 sp|P02649|APOE_HUMAN 36 kDa 
Complement factor B OS=Homo sapiens GN=CFB PE=1 
SV=2 sp|P00751|CFAB_HUMAN 86 kDa 
Complement component C8 beta chain OS=Homo 
sapiens GN=C8B PE=1 SV=3 sp|P07358|CO8B_HUMAN 67 kDa 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 sp|P02790|HEMO_HUMAN 52 kDa 
Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 sp|P04264|K2C1_HUMAN 66 kDa 
C-reactive protein OS=Homo sapiens GN=CRP PE=1 
SV=1 sp|P02741|CRP_HUMAN 25 kDa 
Complement C1s subcomponent OS=Homo sapiens 
GN=C1S PE=1 SV=1 sp|P09871|C1S_HUMAN 77 kDa 
Alpha-1-antichymotrypsin OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 sp|P01011|AACT_HUMAN 48 kDa 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 
SV=1 sp|P01008|ANT3_HUMAN 53 kDa 
Complement component C7 OS=Homo sapiens GN=C7 
PE=1 SV=2 sp|P10643|CO7_HUMAN 94 kDa 
Vitamin K-dependent protein S OS=Homo sapiens 
GN=PROS1 PE=1 SV=1 sp|P07225|PROS_HUMAN 75 kDa 
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 sp|P02760|AMBP_HUMAN 39 kDa 
Complement component C8 alpha chain OS=Homo 
sapiens GN=C8A PE=1 SV=2 sp|P07357|CO8A_HUMAN 65 kDa 
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 sp|P01042|KNG1_HUMAN 72 kDa 
Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH 
PE=1 SV=3 sp|P02749|APOH_HUMAN 38 kDa 
Ig lambda-2 chain C regions OS=Homo sapiens 
GN=IGLC2 PE=1 SV=1 sp|P0CG05|LAC2_HUMAN 11 kDa 
Complement C1q subcomponent subunit B OS=Homo 
sapiens GN=C1QB PE=1 SV=3 sp|P02746|C1QB_HUMAN 27 kDa 
Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 sp|P10909|CLUS_HUMAN 52 kDa 
Complement component C9 OS=Homo sapiens GN=C9 
PE=1 SV=2 sp|P02748|CO9_HUMAN 63 kDa 
Ig heavy chain V-II region ARH-77 OS=Homo sapiens 
PE=4 SV=1 sp|P06331|HV209_HUMAN 16 kDa 
Ig heavy chain V-III region TRO OS=Homo sapiens PE=1 
SV=1 sp|P01762|HV301_HUMAN 13 kDa 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 sp|P06727|APOA4_HUMAN 45 kDa 
 29 
PE=1 SV=3 
Ig heavy chain V-III region BRO OS=Homo sapiens PE=1 
SV=1 sp|P01766|HV305_HUMAN 13 kDa 
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 sp|P06396|GELS_HUMAN 86 kDa 
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 
SV=2 sp|P01625|KV402_HUMAN 13 kDa 
Ig heavy chain V-III region 23 OS=Homo sapiens 
GN=IGHV3-23 PE=1 SV=2 sp|P01764|HV303_HUMAN 13 kDa 
Serum paraoxonase/arylesterase 1 OS=Homo sapiens 
GN=PON1 PE=1 SV=3 sp|P27169|PON1_HUMAN 40 kDa 
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 sp|P04004|VTNC_HUMAN 54 kDa 
Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 
SV=2 sp|P07996|TSP1_HUMAN 129 kDa 
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 
PE=1 SV=1 sp|P63261|ACTG_HUMAN 42 kDa 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 
SV=1 sp|P01781|HV320_HUMAN 13 kDa 
Complement C4-A OS=Homo sapiens GN=C4A PE=1 
SV=2 sp|P0C0L4|CO4A_HUMAN 193 kDa 
Complement factor I OS=Homo sapiens GN=CFI PE=1 
SV=2 sp|P05156|CFAI_HUMAN 66 kDa 
Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 
SV=1 sp|P01597|KV105_HUMAN 12 kDa 
Haptoglobin-related protein OS=Homo sapiens 
GN=HPR PE=2 SV=2 sp|P00739|HPTR_HUMAN 39 kDa 
Complement component C8 gamma chain OS=Homo 
sapiens GN=C8G PE=1 SV=3 sp|P07360|CO8G_HUMAN 22 kDa 
Galectin-3-binding protein OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 sp|Q08380|LG3BP_HUMAN 65 kDa 
Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2 sp|O75636|FCN3_HUMAN 33 kDa 
Coagulation factor XIII B chain OS=Homo sapiens 
GN=F13B PE=1 SV=3 sp|P05160|F13B_HUMAN 76 kDa 
Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 sp|Q9Y490|TLN1_HUMAN 270 kDa 
Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 
PE=1 SV=3 sp|P05546|HEP2_HUMAN 57 kDa 
Lipopolysaccharide-binding protein OS=Homo sapiens 
GN=LBP PE=1 SV=3 sp|P18428|LBP_HUMAN 53 kDa 
Ig kappa chain V-III region B6 OS=Homo sapiens PE=1 
SV=1 sp|P01619|KV301_HUMAN 12 kDa 
Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 
PE=1 SV=3 sp|P08697|A2AP_HUMAN 55 kDa 
Ig kappa chain V-I region Gal OS=Homo sapiens PE=1 
SV=1 sp|P01599|KV107_HUMAN 12 kDa 
Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 sp|P23142|FBLN1_HUMAN 77 kDa 
Ig heavy chain V-III region GA OS=Homo sapiens PE=1 
SV=1 sp|P01769|HV308_HUMAN 13 kDa 
Serum amyloid P-component OS=Homo sapiens 
GN=APCS PE=1 SV=2 sp|P02743|SAMP_HUMAN 25 kDa 
Complement C1q subcomponent subunit C OS=Homo 
sapiens GN=C1QC PE=1 SV=3 sp|P02747|C1QC_HUMAN 26 kDa 
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Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 
SV=1 sp|P03952|KLKB1_HUMAN 71 kDa 
Plasma protease C1 inhibitor OS=Homo sapiens 
GN=SERPING1 PE=1 SV=2 sp|P05155|IC1_HUMAN 55 kDa 
Ig heavy chain V-I region 5 (Fragment) OS=Homo 
sapiens GN=IGKV1-5 PE=4 SV=2 sp|P01602|KV110_HUMAN 13 kDa 
Complement C1q subcomponent subunit A OS=Homo 
sapiens GN=C1QA PE=1 SV=2 sp|P02745|C1QA_HUMAN 26 kDa 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 
SV=1 sp|P01598|KV106_HUMAN 12 kDa 
Ig delta chain C region OS=Homo sapiens GN=IGHD 
PE=1 SV=2 sp|P01880|IGHD_HUMAN 42 kDa 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 
SV=1 sp|P01019|ANGT_HUMAN 53 kDa 
Insulin-like growth factor-binding protein complex acid 
labile subunit OS=Homo sapiens GN=IGFALS PE=1 SV=1 sp|P35858|ALS_HUMAN 66 kDa 
N-acetylmuramoyl-L-alanine amidase OS=Homo 
sapiens GN=PGLYRP2 PE=1 SV=1 sp|Q96PD5|PGRP2_HUMAN 62 kDa 
Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 
PE=1 SV=3 sp|P02753|RET4_HUMAN 23 kDa 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG 
PE=1 SV=1 sp|P02765|FETUA_HUMAN 39 kDa 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 sp|P06681|CO2_HUMAN 83 kDa 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens 
GN=LRG1 PE=1 SV=2 sp|P02750|A2GL_HUMAN 38 kDa 
Ig heavy chain V-I region EU OS=Homo sapiens PE=1 
SV=1 sp|P01742|HV101_HUMAN 12 kDa 
Immunoglobulin J chain OS=Homo sapiens GN=JCHAIN 
PE=1 SV=4 sp|P01591|IGJ_HUMAN 18 kDa 
Pigment epithelium-derived factor OS=Homo sapiens 
GN=SERPINF1 PE=1 SV=4 sp|P36955|PEDF_HUMAN 46 kDa 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 sp|P01877|IGHA2_HUMAN 37 kDa 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens 
GN=ORM2 PE=1 SV=2 sp|P19652|A1AG2_HUMAN 24 kDa 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 
PE=1 SV=1 sp|P02652|APOA2_HUMAN 11 kDa 
C4b-binding protein beta chain OS=Homo sapiens 
GN=C4BPB PE=1 SV=1 sp|P20851|C4BPB_HUMAN 28 kDa 
Complement factor H-related protein 1 OS=Homo 
sapiens GN=CFHR1 PE=1 SV=2 sp|Q03591|FHR1_HUMAN 38 kDa 
Ig heavy chain V-III region CAM OS=Homo sapiens 
PE=1 SV=1 sp|P01768|HV307_HUMAN 14 kDa 
Ig lambda chain V-III region LOI OS=Homo sapiens 
PE=1 SV=1 sp|P80748|LV302_HUMAN 12 kDa 
Coagulation factor XIII A chain OS=Homo sapiens 
GN=F13A1 PE=1 SV=4 sp|P00488|F13A_HUMAN 83 kDa 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 
SV=1 sp|P01700|LV102_HUMAN 12 kDa 
Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 
SV=1 sp|P05090|APOD_HUMAN 21 kDa 
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Ig kappa chain V-III region CLL OS=Homo sapiens PE=4 
SV=2 sp|P04207|KV308_HUMAN 14 kDa 
Ig heavy chain V-I region HG3 OS=Homo sapiens PE=3 
SV=1 sp|P01743|HV102_HUMAN 13 kDa 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens 
GN=ORM1 PE=1 SV=1 sp|P02763|A1AG1_HUMAN 24 kDa 
Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 sp|P04040|CATA_HUMAN 60 kDa 
Carboxypeptidase N subunit 2 OS=Homo sapiens 
GN=CPN2 PE=1 SV=3 sp|P22792|CPN2_HUMAN 61 kDa 
Ig kappa chain V-III region NG9 (Fragment) OS=Homo 
sapiens PE=2 SV=1 sp|P01621|KV303_HUMAN 11 kDa 
Ig kappa chain V-I region Mev OS=Homo sapiens PE=1 
SV=1 sp|P01612|KV120_HUMAN 12 kDa 
Ig heavy chain V-III region HIL OS=Homo sapiens PE=1 
SV=1 sp|P01771|HV310_HUMAN 14 kDa 
von Willebrand factor OS=Homo sapiens GN=VWF 
PE=1 SV=4 sp|P04275|VWF_HUMAN 309 kDa 
Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 
SV=2 sp|P00740|FA9_HUMAN 52 kDa 
Ig kappa chain V-II region RPMI 6410 OS=Homo 
sapiens PE=4 SV=1 sp|P06310|KV206_HUMAN 15 kDa 
Hepatocyte growth factor-like protein OS=Homo 
sapiens GN=MST1 PE=1 SV=2 sp|P26927|HGFL_HUMAN 80 kDa 
Apolipoprotein M OS=Homo sapiens GN=APOM PE=1 
SV=2 sp|O95445|APOM_HUMAN 21 kDa 
Ig kappa chain V-III region VG (Fragment) OS=Homo 
sapiens PE=1 SV=1 sp|P04433|KV309_HUMAN 13 kDa 
Properdin OS=Homo sapiens GN=CFP PE=1 SV=2 sp|P27918|PROP_HUMAN 51 kDa 
Ig kappa chain V-I region WEA OS=Homo sapiens PE=1 
SV=1 sp|P01610|KV118_HUMAN 12 kDa 
Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 
SV=1 sp|P01617|KV204_HUMAN 12 kDa 
Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 
PE=1 SV=2 sp|Q96IY4|CBPB2_HUMAN 48 kDa 
Ig kappa chain V-I region CAR OS=Homo sapiens PE=1 
SV=1 sp|P01596|KV104_HUMAN 12 kDa 
Ig lambda-7 chain C region OS=Homo sapiens 
GN=IGLC7 PE=4 SV=2 sp|A0M8Q6|LAC7_HUMAN 11 kDa 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 sp|P21333|FLNA_HUMAN 281 kDa 
Ig lambda chain V-V region DEL OS=Homo sapiens 
PE=1 SV=1 sp|P01719|LV501_HUMAN 11 kDa 
Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 
SV=1 sp|P01767|HV306_HUMAN 12 kDa 
Ig kappa chain V-I region AG OS=Homo sapiens PE=1 
SV=1 sp|P01593|KV101_HUMAN 12 kDa 
Transforming growth factor-beta-induced protein ig-
h3 OS=Homo sapiens GN=TGFBI PE=1 SV=1 sp|Q15582|BGH3_HUMAN 75 kDa 
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 
SV=2 sp|P12814|ACTN1_HUMAN 103 kDa 
Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 SV=2 sp|Q15485|FCN2_HUMAN 34 kDa 
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Ig lambda chain V-III region SH OS=Homo sapiens PE=1 
SV=1 sp|P01714|LV301_HUMAN 11 kDa 
Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 
SV=3 sp|P00748|FA12_HUMAN 68 kDa 
Plasma serine protease inhibitor OS=Homo sapiens 
GN=SERPINA5 PE=1 SV=3 sp|P05154|IPSP_HUMAN 46 kDa 
Ig lambda chain V-I region NEW OS=Homo sapiens 
PE=1 SV=1 sp|P01701|LV103_HUMAN 11 kDa 
Ig lambda chain V-II region NIG-84 OS=Homo sapiens 
PE=1 SV=1 sp|P04209|LV211_HUMAN 12 kDa 
Ig heavy chain V-III region WEA OS=Homo sapiens 
PE=1 SV=1 sp|P01763|HV302_HUMAN 12 kDa 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD 
PE=1 SV=2 sp|P02042|HBD_HUMAN 16 kDa 
Coagulation factor V OS=Homo sapiens GN=F5 PE=1 
SV=4 sp|P12259|FA5_HUMAN 252 kDa 
Extracellular matrix protein 1 OS=Homo sapiens 
GN=ECM1 PE=1 SV=2 sp|Q16610|ECM1_HUMAN 61 kDa 
Glyceraldehyde-3-phosphate dehydrogenase 
OS=Homo sapiens GN=GAPDH PE=1 SV=3 sp|P04406|G3P_HUMAN 36 kDa 
Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 
SV=1 sp|P01616|KV203_HUMAN 12 kDa 
Putative V-set and immunoglobulin domain-
containing-like protein IGHV4OR15-8 OS=Homo 
sapiens GN=IGHV4OR15-8 PE=5 SV=2 sp|A6NJ16|IV4F8_HUMAN 14 kDa 
Ig lambda chain V-II region NEI OS=Homo sapiens PE=1 
SV=1 sp|P01705|LV202_HUMAN 12 kDa 
Band 3 anion transport protein OS=Homo sapiens 
GN=SLC4A1 PE=1 SV=3 sp|P02730|B3AT_HUMAN 102 kDa 
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 
SV=5 sp|P32119|PRDX2_HUMAN 22 kDa 
Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3 sp|P05452|TETN_HUMAN 23 kDa 
Serum amyloid A-1 protein OS=Homo sapiens 
GN=SAA1 PE=1 SV=1 sp|P0DJI8|SAA1_HUMAN 14 kDa 
L-lactate dehydrogenase A chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 sp|P00338|LDHA_HUMAN 37 kDa 
Complement factor H-related protein 5 OS=Homo 
sapiens GN=CFHR5 PE=1 SV=1 sp|Q9BXR6|FHR5_HUMAN 64 kDa 
Mannose-binding protein C OS=Homo sapiens 
GN=MBL2 PE=1 SV=2 sp|P11226|MBL2_HUMAN 26 kDa 
EGF-containing fibulin-like extracellular matrix protein 
1 OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 sp|Q12805|FBLN3_HUMAN 55 kDa 
Ig kappa chain V-I region Kue OS=Homo sapiens PE=1 
SV=1 sp|P01604|KV112_HUMAN 12 kDa 
Ig kappa chain V-IV region STH (Fragment) OS=Homo 
sapiens PE=1 SV=1 sp|P83593|KV405_HUMAN 12 kDa 
Ig kappa chain V-I region Roy OS=Homo sapiens PE=1 
SV=1 sp|P01608|KV116_HUMAN 12 kDa 
Coagulation factor XI OS=Homo sapiens GN=F11 PE=1 
SV=1 sp|P03951|FA11_HUMAN 70 kDa 
Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 sp|P06702|S10A9_HUMAN 13 kDa 
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SV=1 
Polymeric immunoglobulin receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 sp|P01833|PIGR_HUMAN 83 kDa 
Phosphatidylinositol-glycan-specific phospholipase D 
OS=Homo sapiens GN=GPLD1 PE=1 SV=3 sp|P80108|PHLD_HUMAN 92 kDa 
Ig heavy chain V-II region WAH OS=Homo sapiens PE=1 
SV=1 sp|P01824|HV206_HUMAN 14 kDa 
Ig heavy chain V-III region BUR OS=Homo sapiens PE=1 
SV=1 sp|P01773|HV312_HUMAN 13 kDa 
Apolipoprotein C-III OS=Homo sapiens GN=APOC3 
PE=1 SV=1 sp|P02656|APOC3_HUMAN 11 kDa 
Ig kappa chain V-I region Rei OS=Homo sapiens PE=1 
SV=1 sp|P01607|KV115_HUMAN 12 kDa 
Mannan-binding lectin serine protease 1 OS=Homo 
sapiens GN=MASP1 PE=1 SV=3 sp|P48740|MASP1_HUMAN 79 kDa 
Zinc-alpha-2-glycoprotein OS=Homo sapiens 
GN=AZGP1 PE=1 SV=2 sp|P25311|ZA2G_HUMAN 34 kDa 
Adiponectin OS=Homo sapiens GN=ADIPOQ PE=1 SV=1 sp|Q15848|ADIPO_HUMAN 26 kDa 
Ig lambda chain V region 4A OS=Homo sapiens PE=4 
SV=1 sp|P04211|LV001_HUMAN 12 kDa 
Ig kappa chain V-III region GOL OS=Homo sapiens PE=1 
SV=1 sp|P04206|KV307_HUMAN 12 kDa 
78 kDa glucose-regulated protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 sp|P11021|GRP78_HUMAN 72 kDa 
Sulfhydryl oxidase 1 OS=Homo sapiens GN=QSOX1 
PE=1 SV=3 sp|O00391|QSOX1_HUMAN 83 kDa 
Ig lambda chain V-II region BUR OS=Homo sapiens 
PE=1 SV=1 sp|P01708|LV205_HUMAN 12 kDa 
Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 
SV=1 sp|P02654|APOC1_HUMAN 9 kDa 
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 
SV=1 sp|P05109|S10A8_HUMAN 11 kDa 
Lumican OS=Homo sapiens GN=LUM PE=1 SV=2 sp|P51884|LUM_HUMAN 38 kDa 
Monocyte differentiation antigen CD14 OS=Homo 
sapiens GN=CD14 PE=1 SV=2 sp|P08571|CD14_HUMAN 40 kDa 
Complement factor D OS=Homo sapiens GN=CFD PE=1 
SV=5 sp|P00746|CFAD_HUMAN 27 kDa 
Talin-2 OS=Homo sapiens GN=TLN2 PE=1 SV=4 sp|Q9Y4G6|TLN2_HUMAN 272 kDa 
Ig kappa chain V-I region Ka OS=Homo sapiens PE=1 
SV=1 sp|P01603|KV111_HUMAN 12 kDa 
Fermitin family homolog 3 OS=Homo sapiens 
GN=FERMT3 PE=1 SV=1 sp|Q86UX7|URP2_HUMAN 76 kDa 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 sp|P06733|ENOA_HUMAN 47 kDa 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial OS=Homo sapiens GN=CPS1 PE=1 SV=2 sp|P31327|CPSM_HUMAN 165 kDa 
Abnormal spindle-like microcephaly-associated protein 
OS=Homo sapiens GN=ASPM PE=1 SV=2 sp|Q8IZT6|ASPM_HUMAN 410 kDa 
Titin OS=Homo sapiens GN=TTN PE=1 SV=4 sp|Q8WZ42|TITIN_HUMAN 3816 kDa 
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Figure 3.  Trauma Exosome Protein Localization.  A. Exosomal proteins were 
categorized for their biological function.  B. Exosomal proteins were next categorized 
according to their molecular function.  C. Exosomal proteins were next categorized as to 
their cellular component. 
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Proteins possessed the following 19 biological functions: Biological Regulation (186), 
Biological Process (186), Cellular Process (183), Stimulus Response (165), Metabolic 
Process (147), Localization (131), Establishment of Localization (125), Multicellular 
Organismal Process (82), Developmental Process (56), Multi-organism Process (39), 
Biological Adhesion (16), Locomotion (15), Reproductive Process (9), Reproduction (9), 
Viral Replication (9), Growth (6) Cell Killing (3), and Rhythmic Process (3). Proteins 
were further stratified according to Molecular Function (Figure 3B) and Cellular 
Compartments (Figure 3C).  The proteins possessed the following 13 molecular 
functions: undetermined molecular function (171), Binding (158), Chemoattractant 
activity (1), Chemorepellent activity (1), Transcription regulator activity (2), Auxiliary 
transport protein activity (3), Antioxidant activity (8), Structural molecule activity (10), 
Molecular transducer activity (13), Transporter activity (14), Enzyme regulator activity 
(29), Catalytic activity (93), and Unknown (15) (Figure 3B).  The proteins represented 
14 different cellular compartments: Extracellular region (182), Membrane (128), 
Ribosome (1), Mitochondrion (4), Endosome (8), Golgi apparatus (14), Endoplasmic 
reticulum (14), Cytoskeleton (15), Organelle membrane (15), Nucleus (21), Organelle 
part (56), Cytoplasm (71), Intracellular organelle (73) and Plasma membrane (118) 
(Figure 3C).  
 
 Protein Expression Across Different GCS Classifications. 
Of the 186 total proteins found, 134 were held in common between all three 
experimental groups (Figure 2 and Table I). Additionally, sixteen were shared between 
two groups (Table III).  Specifically, between Groups A (No Significant Trauma) and 
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B/C (Mild-to-Moderate Trauma) nine proteins were found to be in common: Ig kappa 
chain V-III region B6, Ig lambda chain V-III region LOI, Ig heavy chain V-I region HG3, 
Hemoglobin subunit delta, Peroxiredoxin-2, Coagulation factor XI, Polymeric 
immunoglobulin receptor, Phosphatidylinositol-glycan-specific phospholipase D, and 
Apolipoprotein C-III.  Groups B/C (Mild-to-Moderate Trauma) and D (Severe Trauma), 
shared four proteins: Ig heavy chain V-III region HIL, von Willebrand factor, 
Coagulation factor V, and Mannan-binding lectin serine protease. Between our two most 
disparate groups of trauma patients, groups A (No Significant Trauma) and D (Severe 
Trauma), three (3) proteins were found to be present in both patient subsets: Ig lambda 
chain V-II region NEI, L-lactate dehydrogenase A chain, and Ig kappa chain V-IV region 
STH (Fragment). All of the proteins found to be present in two groups are found in Table 
III. However, differential proteomic expression was observed between our stratified GCS 
classifications as 6 of these proteins were found only in patients that had suffered no 
significant trauma as denoted by GCS score (15): Ig kappa chain V-III region NG9, 
Protein S100-A9, Apolipoprotein C-I, Ig kappa chain V-I region Ka, Fermitin family 
homolog 3, and Alpha-enolase (Table IV). Sixteen proteins were unique to patients that 
had mild-to-moderate trauma as designated by GCS Score (9-12):  Ig kappa chain V-I 
region Gal, Ig kappa chain V-I region EU, Ig kappa chain V-III region CLL, Ig kappa 
chain V-II region TEW, Ig heavy chain V-III region WEA, Tetranectin, EGF-containing 
fibulin-like extracellular matrix protein 1, Adiponectin, Ig lambda chain V region 4A, 
Sulfhydryl oxidase 1, Protein S100-A8, Lumican, Complement factor D, Talin-2, 
Abnormal spindle-like microcephaly-associated protein, and Titin (Table IV). 
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Table III. Proteins Held in Common by Two or more groups. 
Groups A and B/C: 9 Proteins Groups A and D: 3 
Proteins 
Groups B/C and D:  4 
Proteins 
Ig kappa chain V-III region B6  Ig lambda chain V-II 
region NEI  
Ig heavy chain V-III 
region HIL  
Ig lambda chain V-III region 
LOI  
L-lactate dehydrogenase 
A chain von Willebrand factor  
Ig heavy chain V-I region HG3  Ig kappa chain V-IV 
region STH (Fragment) Coagulation factor V  
Hemoglobin subunit delta  
 
Mannan-binding lectin 
serine protease 1  
Peroxiredoxin-2    
Coagulation factor XI    
Polymeric immunoglobulin 
receptor  
  
Phosphatidylinositol-glycan-
specific phospholipase D  
  
Apolipoprotein C-III    
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Table IV. List of Group Specific Proteins 
Group A: 6 Proteins Group B/C: 16 Proteins Group D: 14 Proteins 
Ig kappa chain V-III 
region NG9 (Fragment)  
Ig kappa chain V-I region 
Gal  
Ig kappa chain V-I region 
AG  
Protein S100-A9  
Ig kappa chain V-I region 
EU  
Ig lambda chain V-II 
region NIG-84  
Apolipoprotein C-I  
Ig kappa chain V-III region 
CLL  
Mannose-binding protein 
C  
Ig kappa chain V-I region 
Ka  
Ig kappa chain V-II region 
TEW  
Ig kappa chain V-I region 
Roy  
Fermitin family homolog 3  
Ig heavy chain V-III region 
WEA  
Ig heavy chain V-II region 
WAH  
Alpha-enolase  Tetranectin  
Ig heavy chain V-III 
region BUR  
 EGF-containing fibulin-like 
extracellular matrix protein 
1  
Ig kappa chain V-I region 
Rei  
 Adiponectin  Zinc-alpha-2-glycoprotein  
 Ig lambda chain V region 
4A  
Ig kappa chain V-III 
region GOL  
 
Sulfhydryl oxidase 1  
78 kDa glucose-regulated 
protein  
 
Protein S100-A8  
Ig lambda chain V-II 
region BUR  
 
Lumican  
Monocyte differentiation 
antigen CD14  
 
Complement factor D  
Carbamoyl-phosphate 
synthase (ammonia), 
mitochondrial 
 
Talin-2  
Ig heavy chain V-III 
region BUT 
 Abnormal spindle-like 
microcephaly-associated 
protein  
 
 
Titin  
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Fourteen (14) proteins were found only in patients that had suffered significant trauma as 
designated by GCS score (3-8):  Ig kappa chain V-I region AG, Ig lambda chain V-II 
region NIG-84, Mannose-binding protein C, Ig kappa chain V-I region Roy, Ig heavy 
chain V-II region WAH, Ig heavy chain V-III region BUR, Ig kappa chain V-I region Rei 
Zinc-alpha-2-glycoprotein, Ig kappa chain V-III region GOL, 78 kDa glucose-regulated 
protein, Ig lambda chain V-II region BUR, Monocyte differentiation antigen CD14, and 
Carbamoyl-phosphate synthase (ammonia), mitochondrial (Table IV). 
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Discussion 
The natural history of mild traumatic brain injury (TBI) or concussion remains 
poorly defined and no objective biomarker of physiological recovery exists for clinical 
use 
13
. The National Collegiate Athletic Association (NCAA) and the US Department of 
Defense (DoD) established the Concussion Assessment, Research and Education (CARE) 
Consortium to study the natural history of clinical and neurobiological recovery after 
concussion in the service of improved injury prevention, safety and medical care for 
student-athletes and military personnel 
14
.  Concussion and mTBI research to date has 
largely focused on male athletes in contact sports and has largely ignored the military and 
women
13
.  In addition, most of the assessments have been non-molecular, focused on 
imaging and physical diagnosis. 
The objective of this study was to determine if the addition of molecular 
biomarkers to the physical diagnosis could lead to understanding that would allow injury 
severity to be determined. Exosomal protein analysis of clinical trauma samples taken 
from patients with varying Glasgow Coma Scale (GCS) scores assessed the differential 
protein expression between strata used to define the severity of head injury. Exo-
Proteomic analysis of patients with disparate levels of “trauma severity” lends itself well 
to the discovery of potential trauma-specific biomarkers that can help establish the first 
true differential diagnostic for concussions and mTBI. Utilization of these trauma 
exosomes (TrEx) helps assure that sensitive proteins are still detectable in a post-acute 
phase of head injury, regardless of the degree of severity. Additionally, coupling exo-
proteomic analysis with a non-invasive peripheral blood sample could aid in the 
establishment of a de facto “liquid biopsy” for the assessment of all varieties of TBI. 
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Our results indicate that patient groups with varying GCS scores do exhibit 
differential protein expression in their exosomes. An important limitation of this study is 
the small number of patients that were available for each GCS-categorized group. 
However, we were still able to observe differences in exosomal protein expression 
between our study groups. While we discovered no putative markers of TBI in our 
analysis and our patient samples were aggregated rather than analyzed individually, the 
results of this work indicate a proof of concept that helps validate an exo-proteomic 
approach for the study of traumatic brain injury. Not all patients were verified to have 
TBI as detailed injury descriptions were not given. The ongoing and next steps in 
exosome research include refining the isolation procedure for exosomes, defining the 
appropriate window for isolation, determine what contents are most important for 
diagnosis: mRNAs, miRNAs, lipids and proteins, and to determine which exosomes can 
and cannot cross the blood brain barrier. Further patient studies comparing exosomal 
patient samples would be best served if comparative proteomic analysis were stratified 
according to patient populations representing both verified TBIs as compared to non-TBI 
related injuries. This would aid analysis and help guide the search for definitive TBI-
related biomarkers. The single greatest challenge facing any clinical study of TBI-related 
proteomics is the inherent limitations of the GCS itself. GCS scoring and stratification 
lacks definitive prognostic value, including significant variances in head injury patterns 
and exhibit the potential for skewed triage and treatment due to unrelated factors such as 
hemorrhagic shock and other acute phenomena. Additional measures of injury 
assessment (such as Injury Severity Score, for example) need to be factored in when 
designing and implementing further exo-proteomic studies of TBI. 
 42 
Acknowledgements 
Research reported in this publication was supported by a Loma Linda University 
internal grant to promote collaborative & translational research (GCAT) mechanism.  The 
authors thank Loma Linda University School of Medicine and the Center for Health 
Disparities and Molecular Medicine for supporting this work. 
 
Conflict of Interest 
The authors have declared that no competing interests exist. 
 
 
 43 
References 
1. Coronado VG, Xu L, Basavaraju SV, et al. Surveillance for traumatic brain 
injury-related deaths--United States, 1997-2007. Morbidity and mortality weekly 
report Surveillance summaries (Washington, DC : 2002). 2011;60(5):1-32. 
 
2. Mitra B, Rau TF, Surendran N, et al. Plasma micro-RNA biomarkers for 
diagnosis and prognosis after traumatic brain injury: A pilot study. Journal of 
clinical neuroscience : official journal of the Neurosurgical Society of 
Australasia. 2017;38:37-42. 
 
3. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A 
practical scale. Lancet (London, England). 1974;2(7872):81-84. 
 
4. Masel BE, DeWitt DS. Traumatic brain injury: a disease process, not an event. 
Journal of neurotrauma. 2010;27(8):1529-1540. 
 
5. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta 
pathology: a link to Alzheimer's disease? Nature reviews Neuroscience. 
2010;11(5):361-370. 
 
6. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in 
athletes: progressive tauopathy after repetitive head injury. Journal of 
neuropathology and experimental neurology. 2009;68(7):709-735. 
 
7. McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic 
traumatic encephalopathy. Brain : a journal of neurology. 2013;136(Pt 1):43-64. 
 
8. Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, et al. Rapid accumulation 
of endogenous tau oligomers in a rat model of traumatic brain injury: possible 
link between traumatic brain injury and sporadic tauopathies. The Journal of 
biological chemistry. 2013;288(23):17042-17050. 
 
9. Xiong Y, Mahmood A, Chopp M. Emerging potential of exosomes for treatment 
of traumatic brain injury. Neural Regen Res. 2017;12(1):19-22. 
 
10. Kalani A, Tyagi A, Tyagi N. Exosomes: mediators of neurodegeneration, 
neuroprotection and therapeutics. Mol Neurobiol. 2014;49(1):590-600. 
 
11. Yang Y, Ye Y, Su X, He J, Bai W, He X. MSCs-Derived Exosomes and 
Neuroinflammation, Neurogenesis and Therapy of Traumatic Brain Injury. Front 
Cell Neurosci. 2017;11:55. 
 
12. Turay D, Khan S, Diaz Osterman CJ, et al. Proteomic Profiling of Serum-Derived 
Exosomes from Ethnically Diverse Prostate Cancer Patients. Cancer 
investigation. 2016;34(1):1-11. 
 44 
13. Broglio SP, McCrea M, McAllister T, et al. A National Study on the Effects of 
Concussion in Collegiate Athletes and US Military Service Academy Members: 
The NCAA-DoD Concussion Assessment, Research and Education (CARE) 
Consortium Structure and Methods. Sports Med. 2017. 
 
14. National Collegiate Athletic Association. NCAA, DOD launch Mind Matters 
Challenge. 2014. http://wwwncaaorg/about/resources/media-center/news/ncaa-
dod-launch-mind-matters-challenge. Accessed 20 March 2017. 
 
 45 
CHAPTER THREE 
 
Response to Comment on Moyron et al., Differential protein expression in exosomal 
samples taken from trauma patients.  Proteomics Clinical Application. 2017 May 25. 
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We thank Dr. Wu and his colleagues
1
 for critically reviewing our study to 
establish a panel of trauma markers to increase the likelihood of successfully diagnosing, 
treating and predicting concussions and traumatic brain injuries (TBI)
2
.  We do not 
disagree that a different baseline of patients’ demographic characteristics in the groups 
that we chose, based solely on the Glasgow Comma Score (GCS), could cause possible 
bias.  In fact, though our results did indicate that patient groups with varying GCS scores 
did exhibit differential protein expression in their exosomes, we clearly state many 
limitations in the study. Of note, not all the patients had verified TBI and perhaps most 
significant, these results were from aggregated patient samples rather than from patients 
analyzed individually. Nevertheless, this manuscript’s intent was to report a proof of 
concept, that the exo-proteomic approach could be useful in the study of traumatic brain 
injury and that the ongoing and next steps in exosome research include refining the 
isolation procedure for exosomes, defining the appropriate window for isolation, 
determine what contents are most important for diagnosis: mRNAs, miRNAs, DNA, 
lipids and proteins, and to determine which exosomes can and cannot cross the blood 
brain barrier
2
. We thank Dr. Wu and colleagues for their comments
1
 as we recognize the 
value in determining if patient demographics such as age, gender and perhaps even ethnic 
origin could present disparity expression of exosomal biomarkers or the quantity of a 
specific or panel of biomarkers.  However, discovery of this marker or marker panel to 
determine severity of injury would be best served if comparative proteomic analysis were 
stratified according to patient populations representing both verified TBI as compared to 
non-TBI related injuries. This would aid analysis and help guide the search for definitive 
TBI-related biomarkers of TBI severity. This work was not meant to be supportive but to 
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expose the limitations of the GCS itself in defining the level of trauma a patient having 
TBI would have and their prognosis and recovery. GCS scoring and stratification lacks 
definitive prognostic value
3
, including significant variances in head injury patterns and 
exhibit the potential for skewed triage and treatment due to unrelated factors such as 
hemorrhagic shock and other acute phenomena
4
. 
With that in mind, the current criteria used for evaluation of concussive trauma 
are outdated
5
 and are limited to the assessment of behavioral symptoms
6,7
.  This standard 
for diagnosis is woefully insufficient, even when coupled with GCS score, Injury 
Severity Score (ISS) and other predominately utilized clinical modalities
8
. This fact is 
becoming increasingly clear, not due solely to the subjective nature of emergency 
department assessments of injury severity, but rather to the vastly differing presentations 
of traumatic brain injuries and the relative lack of primacy placed upon them in relation 
to more “significant” injuries with more obvious gross damage8. The current modalities 
need to be supplemented with proteomic profiling that is specifically tailored to the 
definitive diagnosis of concussive or sub-concussive trauma
9,10
. 
Continuing research of concussions and TBI would be best served by utilizing a 
multifactorial, multidisciplinary approach.  Future studies could compare exosomal 
proteomic profiling of patients with verified TBI (SAH, SDH and ICH for example), as 
stratified according to significant findings on radiologic studies or other scans (fMRI, 
MRI, CT) compared with those of patients with similar injury mechanisms (automobile 
vs. pedestrian, motor vehicle accidents, assaults, blunt and penetrating trauma) that do not 
have verifiable TBI
11,12
. GCS scores should still be utilized, however adhering to the 
present GCS categorical stratifications (mild vs. moderate vs. severe) as the primary 
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stratification tool and essential factor for patient enrollment would be inadvisable. In 
addition, after admission and assessment, the ideal enrolled patients would need to be 
assessed and/or treated by multiple in-patient and out-patient services (orthopedics, 
neurosurgery, acute care surgery, emergency medicine etc.) and receive care “in 
concert”13. Ideally, treatment of symptomology and outcome assessment would be a 
cross-pollination of work from diverse clinical and research disciplines such as 
psychology, psychiatry, and neuroscience. 
In addition, Next Generation Sequencing (NGS) of total exosomal RNA can, and 
should, be analyzed concurrently with exosomal proteomic analysis. Combining both 
NGS and proteomic analysis might ultimately lead to the establishment of a fuller picture 
of the underlying systemic impact of head trauma and a greater understanding of the 
acute phases of concussive and sub concussive trauma, disease progression, and predict 
the early onset of post concussive syndrome (PCS) and chronic traumatic encephalopathy 
(CTE)
14,15
. Ideally, the best approach is non-invasive or minimally invasive.  Non-
invasive methods, such as a peripheral blood draw, coupled with exo-proteomic analysis 
lend themselves exceptionally well to this type of biomarker discovery and the potential 
establishment of a de facto “liquid biopsy” for the diagnosis of head trauma16,17. 
 While the search for novel biomarkers of head trauma continues, delineating their 
prognostic value in terms of recovery, return to activity and likelihood of worsening 
symptoms is of critical importance. It is highly likely that the best diagnostic and 
prognostic tools will be a panel of existing markers of neuronal trauma combined with as 
of yet undiscovered markers. Even in the case where the best diagnostic tool is a panel of 
existing known markers of neuronal trauma (e.g. Tau, NSE, S100B, etc.)
3,18-21
, baseline 
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amounts of these existing markers will need to be established in (relatively) healthy, 
symptom-free individuals and compared with known head trauma patients. It will also 
need to be established what level of these markers is indicative of cellular damage and 
what basal level is elicited in normal cellular repair and turnover. 
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CHAPTER FOUR 
CONCLUSION 
The current understanding of head trauma views concussion and TBI as injuries 
that exist along a spectrum, rather than as discrete events. The mildest head injuries are 
termed subconcussive trauma and the most chronic, debilitating events lead to profound 
systemic dysregulation known as Chronic Traumatic Encephalopathy (CTE). 
Subconcussive events are believed to be those injuries that incur brain damage but do not 
result in noticeable symptoms. More severe than subconcussive events are minor 
traumatic brain injuries where the head either strikes, or is struck by, an object. During 
impact to the head, the brain is pushed against the inside of the skull which can cause 
bruising, bleeding, and tearing of nerve fibers. Although widely varied, symptoms of a 
concussion can include headache, dizziness, slurred speech and fatigue among many 
others. Usually, given time and adequate rest (or cessation of at risk activity) the 
symptoms of a concussion resolve within 10 days. However, if these symptoms persist, 
the classification of the injury changes and is dependent upon the length of time before 
symptom resolution. If symptoms linger for longer than 10 days but less than 
approximately 3 months, the concussion has become a concussive syndrome. If 
symptoms persist for longer than 3 months, up to and including several years, the injury 
is no longer seen as a single episodic event and is termed post concussive syndrome. If 
the symptoms become pervasive and/or permanent, this chronic outgrowth of head 
trauma is known as Chronic Traumatic Encephalopathy (CTE). Currently, the only 
definitive diagnosis for CTE is a post-mortem examination of brain tissue. Most 
tragically, the clinical features of CTE often mirror characteristic of Parkinson’s Disease 
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and Alzheimer’s Disease and like these two devastating conditions there is no known 
cure for the malady of CTE. A graphical depiction of the spectrum of head trauma can be 
found in Figure 4. 
 
 
Figure 4. The Spectrum of Traumatic Brain Injury (TBI). 
 
The constellation of symptoms following a concussion or head trauma is both 
complex and problematic. Proper diagnosis, treatment, and prediction of outcomes 
following any gradation of head injury is difficult and prone to significant error and 
subjective bias. Due to the heterogeneity of symptom presentation and the disparate 
factors underlying pathology, in addition to probable genetic precursors (ApoE4 allelic 
inheritance for example), accurate assessment of injury, severity, and recovery are nearly 
impossible at this juncture.  
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Despite the greater awareness and pronounced increase in funding of research into 
traumatic brain injuries, TBI still impose a significant societal burden in terms of lost 
work time, medical care costs, and neuropsychiatric complications. Each year in the 
United States at least 1,700,000 people sustain TBI. This includes 52,000 deaths, 275,000 
hospitalizations, and 1,365,000 patients treated and released from an emergency 
department. TBI is a contributing factor to 30% of all injury related deaths in the United 
States. It is estimated that 3,200,000–5,300,000 persons currently live with long-term 
physical and neuropsychiatric disabilities attributable to TBI (Murray and Lopez, 1997). 
Even with the increased focus on the assessment of TBI of all severities, much work 
remains to be done to fully elucidate the various causes and outcomes along the spectrum 
of injuries. Following the publication of the preceding work, significant cross-modal, 
multi-center studies in TBI risk factors, etiology, assessment and outcomes have been 
undertaken (Yue, Vassar, Lingsma et al, 2013), with varying degrees of success. 
Researchers are increasingly skeptical of the discovery of the “magic bullet”, one-size-
fits-all biomarker of neuronal or systemic damage as a clear, indisputable indicator of 
traumatic brain injury. Current studies are shifting the onus towards the formulation of 
the aforementioned “trauma panel”: a compendium of proteins or biomarkers whose 
dysregulation and presence in CSF or the peripheral blood may be indicative of a level of 
central nervous system disruption, neuronal damage or systemic loss of homeostatic 
balance. Recently, the Food and Drug Administration approved a “concussion test” via 
peripheral blood draw, that assesses the presence/level of a pair of proteins in the 
peripheral blood: GFAP and UCH-L1at 12 hours after a suspected injury. This is exciting 
news because we specifically highlighted these proteins, amongst others, earlier in this 
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work; however, this is only one of many steps that need to be undertaken to paint a fuller 
picture of this troubling disease/condition.  
  These new discoveries and the renewed focus on the course and impact of TBI 
have laid the groundwork for some truly novel experimental approaches and 
collaborative efforts.  Perhaps some of the most fertile and untapped territory, however, is 
the design and implementation of head injury studies focusing on armed services 
personnel currently deployed, or returning from deployment, in the Middle East and other 
combat zones. Significant numbers of men and women in uniform sustain TBI resulting 
from, and in conjunction with, injuries sustained in combat. In contrast to even some of 
the most rigorously designed multi-center studies of head trauma in academic centers, 
inclusion criteria for a traumatic brain injury study involving armed services personnel 
would be relatively straightforward. Post- acute, and rehabilitation, care provided to 
soldiers by the military could be more centralized which would significantly aid in data 
collection and patient stratification. The significance of focusing on soldiers returning 
from combat deployment is readily apparent: they suffer the worst injuries/TBIs (with the 
possible exception of athletes in contact and combat sports), have the most difficult to 
diagnose and triage combination of symptoms, and exhibit the poorest outcomes. 
Additionally, links and potential cross pollination with PTSD and the societal impact 
have been acknowledged and require further study. Well designed and implemented 
studies with proper triage, outcome assessments and multidisciplinary approaches will 
not only elucidate previously unknown linkages between TBI and various ailments 
(PTSD, neuropsychiatric dysregulation etc.) but facilitate applicable conclusions and 
treatments to the general populace and/or other at-risk groups (contact and combat sports 
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participants). We are on the cusp of a new age in traumatic brain injury research and 
treatment and we believe that an exo-proteomic approach to the study of this disease is 
vital to the discovery of its cure and treatment. 
  It is also vitally important to be aware of the potential for unforeseen impact as 
the efficacy of TBI assessment improves. While the benefits of injury treatment, and 
especially prevention, are self-evident, there are potential pitfalls with implementation of 
protocols designed to minimize risk. With the increased awareness of the dangers of 
concussion in the pediatric population, enrollment in youth football and other contact 
sports is declining precipitously. Armed services personnel experience a wide array of 
injuries while performing tasks essential to their duties. Links between TBI and PTSD are 
suspected and perhaps even probable. Yet the mechanistic underpinnings of how exactly 
the dysregulation caused by concussive events leads to the behaviors observed in post-
traumatic stress have yet to be elucidated. Discovery of a panel of definitive trauma 
specific biomarkers could, and would, lead to a fuller understanding of etiology and 
progression. However, great care must be taken in how to utilize our burgeoning 
knowledge. Removal from participation in contact sports based upon a likelihood of 
injury could be problematic. Determinations of ineligibility for enlistment in the armed 
services or imposed limitations in scope of service or in specific roles that result from 
preemptive testing could have profound negative effects on the culture of service and 
sacrifice inherent in our military. The cost in manpower and personnel have the potential 
to be significant. Therefore, we must tread carefully in how we utilize and implement the 
knowledge that we acquire through the advancements in our methodologies. 
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